NYSE:NVRO - Nevro Stock Price, Price Target & More

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Nevro Corp (NYSE:NVRO) issued its quarterly earnings data on Thursday, February, 22nd. The medical equipment provider reported ($0.15) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.01. The medical equipment provider earned $97.96 million during the quarter, compared to the consensus estimate of $96.87 million. Nevro had a negative return on equity of 16.32% and a negative net margin of 11.53%. The firm's revenue for the quarter was up 38.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.34) earnings per share. View Nevro's Earnings History.

Nevro is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Nevro.

10 brokerages have issued 1-year price targets for Nevro's shares. Their predictions range from $62.00 to $105.00. On average, they expect Nevro's stock price to reach $84.5556 in the next twelve months. This suggests a possible upside of 42.3% from the stock's current price. View Analyst Ratings for Nevro.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Nevro include Hill-Rom (HRC), ICU Medical (ICUI), Haemonetics (HAE), Insulet (PODD), Globus Medical (GMED), Penumbra (PEN), Cantel Medical (CMD), Novocure (NVCR), Merit Medical Systems (MMSI), NuVasive (NUVA), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Luminex (LMNX), Glaukos (GKOS) and Tandem Diabetes Care (TNDM).

Media coverage about NVRO stock has been trending somewhat positive on Monday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Nevro earned a news impact score of 0.21 on Accern's scale. They also assigned media headlines about the medical equipment provider an impact score of 45.61 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Nevro's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (1.24%), Hardman Johnston Global Advisors LLC (0.32%), ZWJ Investment Counsel Inc. (0.16%), Bank of Montreal Can (0.10%), Essex Investment Management Co. LLC (0.03%) and Xact Kapitalforvaltning AB (0.01%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro.

NVRO stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can and Hardman Johnston Global Advisors LLC. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Michael F Demane and Wilfred E Jaeger. View Insider Buying and Selling for Nevro.

NVRO stock was acquired by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Essex Investment Management Co. LLC, ZWJ Investment Counsel Inc. and Xact Kapitalforvaltning AB. View Insider Buying and Selling for Nevro.

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NVRO stock can currently be purchased for approximately $59.43.

Nevro has a market capitalization of $1.78 billion and generates $326.67 million in revenue each year. The medical equipment provider earns $-36,650,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis. Nevro employs 676 workers across the globe.

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]